Glutamine, cancer, and its therapy

American Journal of Surgery

Volumn 172, Issue 5, 1996, Pages 418-424

  Klimberg, V Suzanne ^a,c   McClellan, John L ^b  

^a UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^b CENTRAL ARKANSAS VETERANS HEALTHCARE SYSTEM   (United States)

^c NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

6 DIAZO 5 OXONORLEUCINE; ACIVICIN; ANTINEOPLASTIC AGENT; FLURBIPROFEN; GLUTAMINE; GLUTAMINE DERIVATIVE; GLUTATHIONE; INDOMETACIN; PROSTAGLANDIN SYNTHASE INHIBITOR; RECOMBINANT INTERLEUKIN 2;

ANIMAL CELL; ANIMAL MODEL; BONE MARROW TRANSPLANTATION; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER RADIOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG MECHANISM; GLUTATHIONE METABOLISM; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LYMPHOKINE ACTIVATED KILLER CELL; MUCOSA INFLAMMATION; NATURAL KILLER CELL; NONHUMAN; ORAL DRUG ADMINISTRATION; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RADIATION DOSE; RADIATION INJURY; RANDOMIZED CONTROLLED TRIAL; REVIEW; SARCOMA; SOLID TUMOR; TOTAL PARENTERAL NUTRITION; ARTICLE; IMMUNE SYSTEM; METABOLISM; MULTIMODALITY CANCER THERAPY; NEOPLASM; PHYSIOLOGY;

CLINICAL TRIALS; COMBINED MODALITY THERAPY; GLUTAMINE; GLUTATHIONE; HUMANS; IMMUNE SYSTEM; KILLER CELLS, NATURAL; NEOPLASMS; RADIATION INJURIES;

EID: 0030294493     PISSN: 00029610     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9610(96)00217-6     Document Type: Article

References (40)

1. 1. Askanazi J, Furst P, Michelson CB, et al. Muscle and plasma amino acids after injury, hypocaloric glucose versus amino acid infusion. Ann Surg. 1980;191:465-472.
2. 2. Kovacevic Z, Morris HP. The role of glutamine in the oxidative Cty metabolism of malignant cells. Cancer Res. 1972;32:326-333.
3. 3. Windmueller HG. Glutamine utilization by the small intestine. Adv Enzymol. 1982;53:202.
4. 4. Ardawi MSM, Newsholme EA. Glutamine metabolism in lymphocytes: its biochemical, physiological and clinical importance. Biochem J. 1982;208:743.
5. 5. Zeilke RH, Ozand PT, Tildon JT. Reciprocal regulation of glucose w and glutamine utilization by cultured human diploid fibroblasts. J Cell Physiol. 1978;95:41-46.
6. 6. Knox WE, Horowitz ML, Friedell GH. The proportionality of w glutaminase content to growth rate and morphology of rat neoplasms. Cancer Res. 1969;29:669-680.
7. 7. Welbourne TC. Ammonia production and glutamine incorporation into glutathione in the functioning rat kidney. Can J Biochem. 1979;57:233-237.
8. 8. Fox AD, Kripke SA, DePaula J, et al. Effect of a glutamine-supplemented enteral diet on methotrexate-induced enterocolitis. JPEN. 1988;12(4):325-331.
9. 9. Klimberg VS, Souba WW, Dotson DJ, Copeland EM. Oral glutamine supports crypt cell turnover and accelerates intestinal healing following abdominal radiation. JPEN. 1989;34.
10. 10. Klimberg VS, Souba WW, Salloum RM, et al. Glutamine enriched diets support muscle glutamine metabolism without stimulating tumor growth. J Surg Res. 1990;48:319-323.
11. 11. Klimberg VS, Nwokedi E, Hutchins LF, et al. Does glutamine facilitate chemotherapy while reducing its toxicity? Surg Forum. 1991;42:16-18.
12. 12. Fahr M, Kornbluth J, Blossom S, et al. GLN enhances immunoregulation of tumor growth. JPEN. 1994;18(6):471.
13. 13. Bergstrom J, Furst P, Noree LO, Vinnars E. Intracellular free amino acid concentrations in human muscle tissue. J Appl Physiol. 1974;36:693-697.
14. 14. Windmueller HG, Spaeth AE. Respiratory fuels and nitrogen metabolism in vivo in small intestine of fed rats. J Biol Chem. 1980;225:107-112.
15. 15. Vinnars E, Bergstrom J, Furst P. Influence of the postoperative state on the intracellular free amino acids in human muscle tissue. Ann Surg. 1975;182:665-671.
16. LI:12-14.
17. 17. Cao Y, Feng Z, Klimberg VS. Glutamine enhances gut glutathione production. Presented at ASPEN, Washington, DC, January 1996.
18. 18. Hong R, Rounds J, Helton W. GLN preserves liver GSH after lethal hepatic injury. Ann Surg. 1992;215(2):114.
19. 19. Rouse K, Nwokedi E. Woodliff J, et al. Glutamine enhances selectivity of chemotherapy through changes in glutathione metabolism. Ann Surg. 1995;221(4):420-426.
20. 20. Souba W, Strebel F, Bul J, et al. Interorgan GLN metabolism in the tumor-bearing rat. J Surg Res. 1988;44:720.
21. 21. Jepson MM, Bates PC, Broadbent P, et al. Relationship between glutamine concentration and protein synthesis in rat skeletal muscle. Am J Physiol. 1988;255(2 pt 1):E166-E172.
22. 22. Klimberg VS, Kornbluth J, Cao Y, et al. Glutamine suppresses PGE2 synthesis and breast cancer growth. J Surg Res. 1996. In press.
23. 23. Klimberg VS, Pappas AA, Nwokedi E, et al. Effect of GLN on tumor concentrations of MTX. Arch Surg. 1992;27(10):1317.
24. 24. Jensen J, Schaefer R, Nwokedi E, et al. Dietary glutamine prevents chronic radiation enteropathy. Ann Surg Oncol. 1993; 1(2):157-163.
25. 25. Jensen JC, Nwokedi E, Baker ML, et al. Glutamine supports host while decreasing tumor glutathione after radiation injury. Presented at the Association for Academic Surgery 26th Annual Meeting, Montreal, Quebec, Canada, November 1992.
26. 26. Klimberg VS, Gregory M, Blossom S, Baker M. Oral glutamine enhances radiosensitivity in rat sarcoma. Presented at the Society of Surgical Oncology, Houston, Texas, 1994.
27. 27. Alverdy JC. Effect of glutamine-supplemented diets on immunology of the gut. JPEN. 1990;14(suppl):109S-113S.
28. 28. Juretic A, Spagnoli GC, Horig H, et al. GLN requirements in the generation of LAK cells. Clin Nutr. 1994;13:42.
29. 29. Liang C, Cattill D, Liang S. GSH regulates IL-2 activity on cytotoxic T-cells. J Biol Chem. 1989;264(23):13519.
30. 30. Herberman RB, Ortaldo JR. NK cells: their role in defense against disease. Science. 1981;214:24-28.
31. 31. Markovic SN, Murasko DM. Inhibition of induction of natural killer activity in mice by general anesthesia (avettin): role of interferon. Clin Immunol Immunopathol. 1991;60:181-189.
32. 32. Rosenberg SA, Lotze MT, Muul LM, et al. A progress report on the treatment of 157 patients with advanced cancer using LAK cells and IL-2 or high-dose IL-2 alone. NEJM. 1987;316:889-897.
33. 33. Baxevanis CN, Reclos GJ, Gritzapis AD, et al. Elevated PGE2 production by monocytes is responsible for the depressed levels of NK & LAK cell function in patients with breast cancer. Cancer. 1993;12:491-501.
34. 34. Buckley BJ, Kent RS, Whorton AR. Regulation of endothelial cell prostaglandin synthesis by glutathione. J Biol Chem. 1991;266:16659-16666.
35. 35. Chance WT, Cao L, Fischer JE. Response of tumor and host to hyperalimentation and antiglutamine treatments. JPEN. 1990;14:122128.
36. 36. Ziegler TR, Benfell K, Smith RJ, et al. Safety and metabolic effects of L-glutamine administration in humans. JPEN. 1990; 14(suppl):137S-146S.
37. 37. Schloerb PR, Amare M. Total parenteral nutrition with glutamine in bone marrow transplantation and other clinical applications (a randomized, double-blind study). JPEN. 1993;17(5):407-413.
38. 38. Ziegler TR, Young LS, Benfell K, et al. Glutamine-supplemented parenteral nutrition improves nitrogen retention and reduces hospital mortality versus standard parenteral nutrition following bone marrow transplantation: a randomized, double-blind trial. Ann Intern Med. 1992;116:821-828.
39. 39. Skubitz KM, Anderson PM. Oral glutamine to prevent k chemotherapy induced stomatitis: a pilot study. J Lab Clin Med. 1996;127(2):223-228.
40. 40. Richards EW, Long CL, Pinkston JA, et al. The role of oral glutamine supplementation in the prevention of radiation-induced enterocolitis in prostate cancer patients. FASEB J. 1992; 6(5):A1680.